جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

2 مُخرَج نتائج البحث عن «GLUE»

مقالوصول مغلق2026

Ubiquitin in Human Diseases: Pathophysiology, Dysfunction and Treatment

Current Pharmaceutical Design · مجلد 32

Ubiquitin machinery is an essential regulatory system that maintains protein stability, degradation, and signalling by balancing ubiquitination and deubiquitination. In addition to its classical function in protein tagging for proteasomal degradation, ubiquitin has several essential cellular functions, including cell-cycle regulation, DNA repair, immunomodulation, intracellular signalling, and cellular stress responses. Abnormal regulation of this highly ordered system has been implicated in the pathogenesis of cancer, neurodegenerative diseases, infectious diseases, metabolic dysfunction, and autoimmunity. Recent developments in structural biology, chemical biology, and proteomics have increased our understanding of ubiquitin signalling and identified new therapeutic targets by revealing context-specific interactions within nodes of the ubiquitinproteasome system. Future approaches to restore proteostasis involve selective inactivation of proteasomal subunits, E3 ligases, and deubiquitinating enzymes (DUBs), as well as novel modalities such as proteolysistargeting chimeras (PROTACs) and molecular glues that redirect ubiquitin-dependent degradation of diseaserelevant proteins. Although preclinical and early clinical studies have demonstrated target specificity, longterm safety remains a challenge for clinical translation. This review provides an overview of ubiquitin's pathophysiological functions in key human diseases, therapeutic interventions, and the potential of ubiquitin-based therapeutic strategies for precision medicine and targeted drug therapy.

ubiquitinubiquitin-proteasome systemubiquitinationdeubiquitination
مراجعةوصول مفتوح20256استشهاد· Semantic Scholar

N-butyl cyanoacrylate glue application in prostate artery embolization for benign prostatic hyperplasia: a systematic review of safety and efficacy

CVIR Endovascular · مجلد 8 (1) · 98-98

BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common urological disorder in older males, often treated with prostate artery embolization (PAE) to alleviate lower urinary tract symptoms. While traditional embolic materials like microspheres are common, issues such as symptom recurrence and non-target embolization remain. This systematic review evaluates the safety and effectiveness of n-butyl cyanoacrylate (NBCA) glue as an alternative embolic agent for PAE. MATERIALS AND METHODS: A thorough search was performed across databases including PubMed, ScienceDirect, Cochrane, Google Scholar, Scopus, and MEDLINE. Studies were included if they assessed NBCA glue for PAE in BPH patients. Exclusions were made for reviews, non-English articles, conference abstracts, and studies not using glue or ethiodized oil mixtures. The Methodological Index for Non-Randomized Studies criteria was used to assess bias risk, and due to varied outcome measures, a narrative synthesis was conducted. RESULTS: Six studies involving 667 patients met the inclusion criteria. The age in mean ± SD across studies ranged from 67.5 ± 7.8 to 72.6 ± 10.5 with most patients presenting with moderate to severe BPH unresponsive to medication. NBCA glue-based procedures showed high technical success rates and shorter procedure times. International Prostate Symptom Score improvement was reported in 83-94% of patients across all studies with associated quality of life significantly enhanced in up to 94% of patients as well. Prostate volume reduction ranged from 11% to 40.5%, depending on follow-up duration. PSA levels and medication use decreased, and erectile function was mostly preserved, though results varied. Minor complications like groin hematomas and post-embolization syndrome occurred in 4-22% of patients, with no major adverse events reported. CONCLUSION: This review assesses NBCA-based glue as a potential embolic agent in PAE for BPH. The evidence suggests promising short-term outcomes with a favorable safety profile, though findings remain preliminary due to small sample sizes and short follow-up. Larger multicenter randomized trials are therefore needed to validate these results and guide clinical practice.

n-butyl cyanoacrylateprostatic artery embolizationbenign prostatic hyperplasiaembolic agents